secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001437749-25-011309
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene: 96% of CNM-Au8-treated MS patients with vision gains also showed MRI remyelination evidence
--------------------------------------------------------------------------------

- 96% of LCLA visual responders had improved MRI DTI metrics (AD/MTR), confirming remyelination and neuronal repair.
- 91% of LCLA visual responders showed multi-focal VEP improvements (latency/amplitude), indicating functional recovery.
- 98% of SDMT cognitive responders exhibited corresponding MRI DTI improvements, linking cognitive gains to repair.
- Data from long-term open-label extension of Phase 2 VISIONARY-MS trial presented at AAN 2025 Late-Breaking Science Session.
- Clene plans to confirm findings in a global Phase 3 trial for CNM-Au8 in multiple sclerosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774925011309/0001437749-25-011309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774925011309/clnn20250407_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-011309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer